NCT05773300进行中（未招募）不适用
Control Population for the Mayo Clinic Adult Congenital Heart Disease Registry
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- Mayo Clinic
- 入组人数
- 66
- 试验地点
- 1
- 主要终点
- Peak Oxygen Uptake
研究概览
简要总结
This research study is being done to provide comparative data to the Mayo Clinic Adult Congenital Heart Disease Registry.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •No current cardiac medications.
- •Systolic BP ≤ 140 mmHg.
- •Diastolic BP ≤ 90 mmHg.
- •Capacity to consent.
排除标准
- •To be assessed via EMR screening.
- •Patient confirmation during screening visit.
- •Screening tests as applicable.
- •History of cardiovascular disease. eGFR <
- •Current orthopedic limitations.
结局指标
主要结局
Peak Oxygen Uptake
时间窗: 6 Months
Peak Oxygen Uptake (L/min) : 1.7 ± 0.1
Peak Right Ventricular - Pulmonary Coupling
时间窗: 6 Months
Peak Right Ventricular - Pulmonary Coupling: (\|%\|/mmHg): 0.786 ± 0.065
次要结局
未报告次要终点
研究者
Alexander C. Egbe
Principal Investigator
Mayo Clinic
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
不适用
A Study to Assess the Pregnancy Outcome in Women Exposed to Dayvigo® During Pregnancy Compared to an Unexposed Control PopulationSleep Initiation and Maintenance DisordersPregnancyNCT06744673Eisai Inc.861
招募中
不适用
GenerationGemelli: Longitudinal Study for the Evaluation of the Maternal Exposome on the Health of the Newborn and ChildMaternal ExposureMaternal Exposure During PregnancyNCT06617650Fondazione Policlinico Universitario Agostino Gemelli IRCCS140
已完成
不适用
Surveillance of Effectiveness/Safety of Artemether-lumefantrine in Patients With MalariaMalariaNCT01228344Novartis Pharmaceuticals324
已完成
1 期
Clinical Trial of 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Chinese Population Aged 2 Years and AbovePneumoniaNCT05815264Ab&B Bio-tech Co., Ltd.JS144
终止
不适用
A Study to Evaluate Growth in Participants Treated With Somatropin (Nutropin) Using NuSpin DeviceGrowth Hormone DeficiencyNCT01243892Genentech, Inc.18